Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (6): 1132-1136.doi: 10.3969/j.issn.1673-8225.2011.06.041

Previous Articles     Next Articles

Effects of high-dose interleukin-2 adoptive immunotherapy on long-term survival after autologous hematopoietic stem cell transplantation for treating malignant lymphoma

Liu Hao1, 2, Guo Zhi1   

  1. 1Department of Hematology, General Hospital of Beijing Military Area Command of Chinese PLA, Beijing  100700, China
    2First Clinical College, Anhui Medical University, Hefei  230032, Anhui Province, China
  • Received:2010-08-16 Revised:2010-10-10 Online:2011-02-05 Published:2011-02-05
  • Contact: Guo Zhi, Master, Associate chief physician, Associate professor, Department of Hematology, General Hospital of Beijing Military Area Command of Chinese PLA, Beijing 100700, China gzdd2004@yahoo.com.cn
  • About author:Liu Hao★, Studying for master’s degree, Department of Hematology, General Hospital of Beijing Military Area Command of Chinese PLA, Beijing 100700, China; First Clinical College, Anhui Medical University, Hefei 230032, Anhui Province, China liuhao.025@gmail.com

PDF

451

Abstract:

BACKGROUND: Adoptive immunotherapy is a hot focus in tumor immunotherapy. Interleukin-2 (IL-2) is a cytokine with multiple kinds of biological activities, and plays an important role in anti-tumor immunity in the body.
OBJECTIVE: To assess clinical efficacy of high-dose IL-2 adoptive immunotherapy after autologous hematopoietic stem cell transplantation (AHSCT) of malignant lymphoma.
METHODS: A total of 30 malignant lymphoma patients treated with high-dose IL-2 after AHSCT (therapy group) were compared with 30 randomly selected malignant lymphoma patients without high-dose IL-2 therapy after AHSCT. T lymphocyte subsets in peripheral blood of both groups were detected. Changes in their immune function were observed, and all patients were followed up.
RESULTS AND CONCLUSION: There was an increase in T lymphocyte subsets CD3+, CD4+, CD8+, CD4+/CD8+ in peripheral blood of the therapy group following AHSCT. The recurrence rate at the end of follow up: 13.3% in therapy group, and 26.7% in control group; median survival time: 14-98 (42±2) months in therapy group, and 8-78 (28±2) months in control group. Results indicated that high-dose IL-2 therapy of malignant lymphoma patients after AHSCT may improve immune function, reduce recurrence rate after transplantation and prolong survival time.

CLC Number: